Related Experiment Video
Updated: Aug 25, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
New therapeutic strategies with antiplatelet agents
1UC Malattie Cerebrovascolari/Stroke Unit, IRCCS "C. Mondino" Foundation, Via Ferrata 6, I-27100 Pavia, Italy. giuseppe.micieli@mondino.it
Insights
Atherothrombotic pathology is a major health concern. Long-term antiplatelet therapy, like clopidogrel, shows efficacy in preventing recurrent events in high-risk patients.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Pharmacology
Background:
- Atherothrombotic pathology poses a significant health risk, particularly for cerebrovascular, cardiac, and systemic ischemic diseases.
- Patients with prior atherothrombotic events face a high risk of recurrence across different vascular territories.
Purpose of the Study:
- To evaluate the efficacy of long-term antiplatelet therapy in secondary prevention of atherothrombotic manifestations.
- To investigate the combined efficacy and safety of aspirin and clopidogrel, drugs with different antiplatelet mechanisms.
Main Methods:
- Utilizing long-term antiplatelet therapy with noncompetitive inhibitors of ADP-induced platelet aggregation, such as clopidogrel.
- Investigating the combination of aspirin and clopidogrel for patients at high risk of atherothrombotic events.
Main Results:
- Clopidogrel demonstrates efficacy in secondary prevention strategies for high-risk patients.
- Preliminary results of combining aspirin and clopidogrel are promising regarding efficacy and safety.
Conclusions:
- Long-term antiplatelet therapy is effective for secondary prevention in high-risk atherothrombotic patients.
- Combining aspirin and clopidogrel warrants further investigation due to promising preliminary outcomes.
Abstract:
Atherothrombotic pathology represents a major health problem and its prevention may be considered a primary, relevant objective in the conditions considered at risk for cerebrovascular, cardiac, and systemic ischemic diseases. Patients with previous manifestations of this disease are in fact considered at high risk of recurrence as events concerning other vascular territories are involved. Long-term antiplatelet therapy with noncompetitive inhibitors of ADP-induced platelet aggregation such as clopidogrel demonstrates the efficacy of this therapeutic approach in different strategies of secondary prevention in patients at high risk of atherothrombotic manifestations. The opportunity to combine the efficacy and safety of drugs with different mechanisms of action on platelet aggregation such as aspirin and clopidogrel is under investigation and preliminary results are very promising.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...